Renal Cancer: Old and New Paradigms , An Issue of Urologic Clinics

1st Edition, Volume 50-2 - March 24, 2023
Editors: Michael L. Blute, Steven L. Chang
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 2 8 6 - 0
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 2 8 7 - 7

In this issue of Urologic Clinics of North America, guest editors Drs. Michael L. Blute and Steven L. Chang bring their considerable expertise to the topic of Renal Cancer: Old and… Read more

Renal Cancer: Old and New Paradigms , An Issue of Urologic Clinics

Purchase options

Info / Buy

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

In this issue of Urologic Clinics of North America, guest editors Drs. Michael L. Blute and Steven L. Chang bring their considerable expertise to the topic of Renal Cancer: Old and New Paradigms. Recent significant advances in the management of renal cancer have expanded beyond simply eliminating disease to preserving and optimizing quality of life. In this issue, top experts highlight historical perspectives as well as current status and future treatments of renal cancer.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Foreword
Preface
Radiologist’s Disease: Imaging for Renal Cancer
Key points
Introduction
Summary
Clinics care points
Disclosure
Evolution in the Pathologic Classification of Renal Neoplasia
Key points
Historical perspectives
What is new in the 2022 World Health Organization classification of renal tumors?
Beyond 2022: future classification and the role of molecular evaluation?
Staging and grading system
2022 World Health Organization classification application in renal mass biopsy
Summary
Disclosure
Biomarkers for the Detection and Surveillance of Renal Cancer
Key points
Introduction
Magnetic resonance imaging
Summary
Declaration of Interests
Diseases of Hereditary Renal Cell Cancers
Key points
Von Hippel–Lindau disease (OMIM 193300)
Succinate dehydrogenases and the hereditary pheochromocytoma/paraganglioma diseases
Renal cell carcinoma and melanoma diseases: MITF (OMIM 614456) and BAP1 (OMIM 614327) genes
PBRM1
Hereditary papillary renal cell carcinoma type 1 (OMIM 1447000)
Hereditary leiomyomatosis with renal cell carcinoma (OMIM 150800)
Birt–Hogg–Dube disease (OMIM 135150)
Rhabdoid tumor predisposing syndromes rhabdoid tumor predisposing syndrome-1 and rhabdoid tumor predisposing syndrome-2 (OMIM 609322 and OMIM 613325)
Challenges in genetic diagnosis of hereditary renal cell carcinoma
Clinics care points
Disclosure
The Changing Role of Renal Mass Biopsy
Key points
Introduction
Future directions
Summary
Clinics care points
Cystic Renal Masses: Old and New Paradigms
Key points
Background
Radiographic diagnosis
Pathologic diagnosis and outcomes
Future directions
Summary
Clinics care points
Disclosure
Long-Term Renal Function Following Renal Cancer Surgery: Historical Perspectives, Current Status, and Future Considerations
Key points
Subchapter 1: Introduction and Definitions
Subchapter 2: Partial versus radical nephrectomy
Subchapter 3: Determinants of glomerular-filtration-rate after partial nephrectomy: ischemia and parenchymal volume loss
Subchapter 4: Predicting new-baseline glomerular filtration rate after radical nephrectomy and partial nephrectomy
Subchapter 5: Ongoing controversies and future directions
Clinics care points
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
Key points
Introduction
Anatomy
Cytoreductive nephrectomy
Preoperative evaluation
Principles of open inferior vena cava thrombectomy
Principles of thrombectomy
Postoperative management
Clinical outcomes
Perioperative complications
On the horizon
Preoperative considerations
Summary
Clinics care points
Disclosures
The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer
Key points
Introduction
Neoadjuvant therapy trials with anti–vascular endothelial growth factor tyrosine kinase inhibitor agents
Neoadjuvant combination (immunotherapy + tyrosine kinase inhibitor) therapies
Other benefits of neoadjuvant therapy
Future directions for neoadjuvant therapy
Adjuvant therapy in high-risk renal cell carcinoma
Adjuvant therapy trials in the cytokine era
Adjuvant therapy trials with anti–vascular endothelial growth factor tyrosine kinase inhibitor agents
Adjuvant therapy trials with immuno-oncology agents
Ongoing adjuvant trials with immunotherapy
Future directions for adjuvant therapy
Summary
Clinics care points
Disclosure
The Great Masquerader’s New Wardrobe in the Modern Era: The Paraneoplastic Manifestations of Renal Cancer
Key points
Introduction
Constitutional and hematologic presentations
Stauffer syndrome
Role of interleukin 6 and cytokines
Hypercalcemia
Neurological manifestations
Cutaneous manifestations
Glucose manifestations
Miscellaneous manifestations
Paraneoplastic syndromes as biomarkers
Summary
Clinics care points
Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma
Key points
Introduction
Retroperitoneal lymphadenectomy for node-positive disease
Cytoreductive nephrectomy
Role of metastasectomy
Summary
Clinics care points
Funding
Declaration of Interests
Radiation Therapy in the Treatment of Localized and Advanced Renal Cancer
Key points
Treatment paradigms for renal cell carcinoma
Future directions
Clinics care points
Disclosure
The Changing Landscape of Immunotherapy for Advanced Renal Cancer
Key points
Introduction
History
Background
Modern immunotherapy
Discussion
Summary
Clinics care points
Disclosure

Life sciences

Physical sciences & Engineering

Social sciences & Humanities

Health

Renal Cancer: Old and New Paradigms , An Issue of Urologic Clinics

Purchase options

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Michael L. Blute

Steven L. Chang